There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > EpCAM


EpCAM Molecule Information

Name:Epithelial cell adhesion molecule
Target Synonym:MIC18;EPCAM;GA733-2 ;Epithelial cell adhesion molecule;EGP;Epithelial cell surface antigen;TACSTD1;hEGP314;KS 1/4 antigen;M1S2;TROP1;Major gastrointestinal tumor-associated protein GA733-2;Epithelial glycoprotein 314;EGP314;M4S1;Cell surface glycoprotein
Number of Launched Drugs:1
Number of Drugs in Clinical Trials:22
Lastest Research Phase:Approved

EpCAM Protein Product ListCompare or Buy

EpCAM Molecule Synonym Name


EpCAM Molecule Background

EpCAM is also known as CO171A, EGP, EGP40,GA7332, KSA, M4S, MIC18, MK1, TROP1, hEGP2, and is a pan-epithelial differentiation antigen that is expressed on almost all carcinomas as 17-1A(mAb) antigen. Its constitutional function is being elucidated. It is intricately linked with the Cadherin-Catenin pathway and hence the fundamental WNT pathway responsible for intracellular signaling and polarity. The epithelial cell adhesion molecule (Ep-CAM) is known to express in most epithelial malignancies and was reported as a tumor marker or a candidate of molecular targeting therapy. Ep-CAM cross signaling with N-cadherin involves Pi3K, resulting in the abrogation of the cadherin adhesion complexes in epithelial cells was reported. And Epithelial cell adhesion molecule (Ep-CAM) recently received increased attention as a prognostic factor in breast cancer.

EpCAM References

EpCAM Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Catumaxomab Approved Trion Research, Neovii Biotech catumaxomab ema

Removab is indicated for the intraperitoneal treatment of malignant ascites in patients with EpCAM-positive carcinomas where standard therapy is not available or no longer feasible.

Neovii Biotech GmbH 2009-04-20 Malignant Ascites Details

EpCAM Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
VB1-050 (Sesen Bio) VBX-050; VB1-050,VBX 050; VB1 050,VBX050; VB1050 Preclinical Sesen Bio Colon cancer, Gastric cancer, Prostate cancer, Liver cancer Details
Anti-EPCAM CAR-T cell therapy (Sinobioway) Phase Ⅱ Sinobioway Cell Therapy Gastric cancer, Liver cancer Details
M-701 M-701 Phase Ⅰ YZY Bio Malignant Ascites Details
Anti-17-1A monoclonal antibody 3622W94 Phase Ⅱ GlaxoSmithKline Non small cell lung cancer (NSCLC), Prostate cancer Details
ING-1 ING-1 Phase Ⅰ Xoma, Aduro BioTech Adenocarcinoma Details
Citatuzumab bogatox VB6-845; VB6-845d Phase Ⅰ Viventia Biotech, Sesen Bio Solid tumours Details
Anti-KSA cancer vaccine (IDM Pharma) Phase Ⅰ IDM Pharma, Walter Reed Army Institute of Research Prostate cancer, Colorectal cancer Details
A-337 A-337 Phase Ⅰ Generon Corporation Solid tumours Details
VB-4011 (Sesen Bio) VB-4011 Preclinical Viventia Biotech, Sesen Bio Cancer Details
VB1-008 (Sesen Bio) VB1-008; VBX-008,VB1 008; VBX 008,VB1008; VBX008 Preclinical Sesen Bio Cancer Details
NP-1 (Sesen Bio) NP-1 (Sesen Bio),NP 1 (Sesen Bio),NP1 (Sesen Bio) Preclinical Sesen Bio Cancer Details
Oportuzumab monatox 4D5MOCB-ETA; VB4-845; VB-4847; VB-845; B-4845 BLA Filing Viventia Biotech, Sesen Bio Bladder cancer Details
Monoclonal antibody BIS-1 Phase Ⅰ University Hospital Groningen Malignant pleural effusion, Renal carcinoma, Malignant Ascites Details
VB-6901 (Sesen Bio) VB-6901 Preclinical Viventia Biotech, Sesen Bio Cancer Details
186Re-NR-LU-10 186Re-NR-LU-10; NR-LU-10-186Re Phase Ⅰ Poniard Pharmaceuticals Solid tumours Details
Anti-EpCAM cancer vaccine (Aphton) IGN-101 Phase Ⅲ Aphton Corporation, Altropus Non small cell lung cancer (NSCLC) Details
AT-003 AT-003 Preclinical Affitech Cancer Details
VB-6050 (Sesen Bio) VB-6050 Preclinical Viventia Biotech, Sesen Bio Cancer Details
Monoclonal antibody 323A3 Phase Ⅰ Centocor, Nonindustrial source Breast cancer, Cancer Details
Edrecolomab Withdrawn Johnson & Johnson, GlaxoSmithKline, Ajinomoto Colorectal cancer Details
Solitumomab AMG-110; MT-110 Phase Ⅰ Micromet Solid tumours Details
Adecatumumab MT-201,MT201 Phase Ⅱ Amgen, Merck Serono Prostate cancer, Breast cancer, Colorectal cancer Details

This web search service is supported by Google Inc.